Kexing Pharmaceuticals' Albumin-Bound Paclitaxel (Apexelsin®) Receives Marketing Authorization from the European Commission

Intelligent Finance APP News: Kexing Biopharm (688136.SH) announced that its partner, Haichang Biotech, recently received a notification from the European Commission. The product introduced by the company, Paclitaxel for Injection (Albumin-bound) (Apexelsin®, hereinafter referred to as "Albumin Paclitaxel"), has been granted marketing approval by the European Commission.

Injectable Albumin-Bound Paclitaxel Offers Clinical Advantages Over Conventional Paclitaxel Injection and Paclitaxel Liposome, With Improved Safety and Patient Compliance, High Clinical Recognition, and Indispensable Value in Cancer Treatment. Albumin-Bound Paclitaxel is Recommended in the European Society for Medical Oncology Guidelines for Treating Breast Cancer, Metastatic Pancreatic Cancer, and Non-Small Cell Lung Cancer. Over the Past Five Years, Cancer Incidence Rates Have Been Rising in Europe, Driving Gradual Growth of Albumin-Bound Paclitaxel Sales in the European Market.

After the albumin paclitaxel received centralized EU marketing authorization, our company’s albumin paclitaxel product can now be marketed and sold in all EU countries. The EU market is an essential part of our company's overseas commercialization strategy. Our company has been actively promoting the establishment and expansion of marketing channels within the EU market. To date, we have signed agreements with partners from 47 countries and regions, including developed markets such as the EU, Canada, and the UK, as well as emerging markets like Brazil and Singapore. The marketing authorization approval for albumin paclitaxel by the European Commission will help our company further accelerate the expansion of overseas markets, enhance our market competitiveness, and will positively impact our future business operations.